Pennsylvania -- (MARKET WIRE) -- April 18, 2007 --18 April 2007
Directors' Dealings
PuriCore Directors Acquire Shares in the Company
MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 18 April 2007-PuriCore (LSE:
PURI), the life sciences company focused on the development and
commercialisation of its novel, safe antimicrobial technology, today
announces that the following Directors have purchased shares in the
Company, as set out below:
Name Number of Purchase
shares Price of Total number of % of issued share
purchased shares shares held capital
Alan Suggett 35,000 60p 35,000 0.02
Jim Walsh 60,000 52p 60,000 0.04
Contacts:
PuriCore plc +1 (484) 321 2700
Greg Bosch, Chief Executive Officer
Keith A. Goldan, Chief Financial Officer
Financial Dynamics +44 (0) 20 7831 3113
Ben Brewerton
John Gilbert
About PuriCore
PuriCore (London Stock Exchange: PURI) is a life sciences company focused
on developing and commercializing proprietary products that safely,
effectively, and naturally kill contagious pathogens. PuriCore's
technology provides a solution to a broad range of markets that depend
upon controlling contamination, including food safety, medical device
disinfection, wound management, and hospitality. The Company's
proprietary technology mimics the human body's production of the natural
antimicrobial hypochlorous acid, which is highly effective in killing
bacteria, viruses, and fungal spores. Deploying hypocholous acid
solutions as soaks, sprays, mists, and in other forms, PuriCore's
technology is designed to limit the spread of infectious disease,
including major public health threats of M. tuberculosis, MRSA, E.coli,
norovirus, avian influenza, HIV, polio virus, Helicobater pylori, and
Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with
offices in Stafford, UK.
To receive additional information on PuriCore, please visit our web site
at
www.puricore.com, which does not form part of this press release.
This information is provided by RNS
The company news service from the London Stock Exchange